Clinical Trial on the Efficacy of Two Ayurvedic Drugs in Non Proliferative Diabetic Retinopathy

Knowledge Attitude and Practice (KAP) of Diabetic Retinopathy Amongst Diabetic Patients - A Cross-Sectional Survey Study and Evaluation of Efficacy of Shilajatu Rasayana with And Without Kanasaindhavadi Anjana in The Management of Pramehaja Timira?NPDR ? An Open Label Two Arm Randomized Comparative Clinical Trial. - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/08/093159

Enrollment

Registered

2025-08-18

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H350- Background retinopathy and retinalvascular changes

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: ? Patients suffering from Type2 DM having mild to moderate NPDR. ? Patients willing for Ayurvedic treatment. ? Patients between 30 to 70 years ? Taking any of Anti Hyperglycemic agents.

Exclusion criteria

Exclusion criteria: ? History of glaucoma ? Severe NPDR with macular thickness above 300 microns ? Patients with moderate or severe cataract changes ? Hypertensive retinopathy changes. ? Patients with PDR and other complications. ? Patients with complications like diabetic nephropathy. ? Patients having systemic diseases like uncontrolled hypertension ? HbA1c is more than 10 after OHA or insulin ? 200mg/dl or more FBS after OHA or insulin ? Patients with Cardiovascular complaints

Design outcomes

Primary

Measure	Time frame
FOR KAP STUDY 1.The changes in the knowledge, attitude and practice (KAP) regarding diabetic retinopathy among diabetic patients. FOR CLINICAL STUDY 2. The changes in retinal hemorrhages in patients of Pramehaja Timira (NPDR) with Shilajatu Rasayana alone and Shilajatu Rasayana with Kanasaindhavadi Anjana. Timepoint: Assessment will be done before treatment, 21st day,49th day and 79th day.	—

Secondary

Measure	Time frame
1.The changes in retinal oedema and number and size of hard exudates in terms of OCT and Fundus photography in patients with Pramehaja timira (NPDR) of both trial groups. 2. The change in the quality of life in terms of visual acuity in patients with Pramehaja Timira (NPDR) of both trial groups. Timepoint: Assessment will be done before treatment, 21st day,49th day and 79th day.	—

Countries

India

Contacts

Public ContactDr BHAVANA K

ALL INDIA INSTITUTE OF AYURVEDA

eyenimi@gmail.com9650715615

Outcome results